Dabrafenib plus trametinib for BRAF mutated anaplastic thyroid cancer provides an effective treatment option for this aggressive cancer with a dismal prognosis. The gene discussed is BRAF; the disease is thyroid gland undifferentiated (anaplastic) carcinoma.